186,625 results match your criteria Thrombolytic Therapy in Stroke


Post-thrombotic syndrome and recurrent thromboembolism in patients with upper extremity deep vein thrombosis: A systematic review and meta-analysis.

Thromb Res 2018 Dec 8;174:34-39. Epub 2018 Dec 8.

Department of Medicine, Division of Hematology, Western University, London, ON, Canada; Department of Epidemiology and Biostatistics, Western University, London, ON, Canada. Electronic address:

Introduction: There is limited data on the occurrence of complications in patients with upper extremity deep vein thrombosis (UEDVT).

Aims: We aimed to determine the frequency of post-thrombotic syndrome (PTS), thrombosis recurrence and major bleeding (MB) in patients with UEDVT.

Material And Methods: We conducted a systematic review of the literature including studies from 1970 onwards. Read More

View Article
December 2018
1 Read

Tissue Plasminogen Activator Causes Brain Microvascular Endothelial Cell Injury After Oxygen Glucose Deprivation by Inhibiting Sonic Hedgehog Signaling.

Neurochem Res 2018 Dec 14. Epub 2018 Dec 14.

Department of Neurosurgery, Renmin Hospital of Wuhan University, No. 9 Zhangzhidong Road, Wuchang District, Wuhan, 430072, Hubei Province, China.

The thrombolytic activity of tissue plasminogen activator (tPA) has undisputed benefits. However, the documented neurotoxicity of tPA raises important issues. Currently, common treatments for stroke might not be optimum if exogenous tPA can pass through the blood-brain barrier and enter the brain, thus adding to the deleterious effects of tPA within the cerebral parenchyma. Read More

View Article
December 2018

Low-dose systemic thrombolytic therapy for treatment of submassive pulmonary embolism: Clinical efficacy but attendant hemorrhagic risks.

Catheter Cardiovasc Interv 2018 Dec 14. Epub 2018 Dec 14.

Department of Cardiovascular Medicine, Diseases, Beaumont Health, Royal Oak, Michigan.

Objectives: The purpose of the present study is to evaluate the safety and efficacy of "low-dose" systemic thrombolytic therapy (TT) for treatment of patients with intermediate-high risk submassive pulmonary embolism (PE).

Background: TT is increasingly utilized in acute submassive PE. Strategies for TT include catheter-directed administration as well as traditional IV systemic therapy. Read More

View Article
December 2018

New subcutaneous PowerFlow port results in cost and time-savings in a busy outpatient apheresis clinic.

J Clin Apher 2018 Dec 12. Epub 2018 Dec 12.

Division of Laboratory Medicine, Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama.

Many vascular access options, such as subcutaneous ports, are currently on the market for use in both medication infusion and for procedures, such as therapeutic plasma exchange and extracorporeal photopheresis. We compared the cost and time necessary to complete apheresis procedures using either Angiodynamic's Vortex or Bard's PowerFlow subcutaneous ports by reviewing our experience on two patients undergoing long-term apheresis treatments with at least 10 procedures with each type of port. We analyzed the cost of needles and thrombolytic therapy, staff time, overall procedure length, and the total time the patient was in the apheresis unit. Read More

View Article
December 2018

Efficacy of SMTP-7, a small-molecule anti-inflammatory thrombolytic, in embolic stroke in monkeys.

Pharmacol Res Perspect 2018 Dec 5;6(6):e00448. Epub 2018 Dec 5.

Department of Applied Biological Science Tokyo Noko University (Tokyo University of Agriculture and Technology) Tokyo Japan.

SMTP-7 ( triprenyl phenol-7) is a small molecule that promotes thrombolysis and suppresses inflammation possibly through plasminogen modulation and soluble epoxide hydrolase (sEH) inhibition, respectively. Here, we demonstrate an efficacy of SMTP-7 in a severe embolic stroke model in monkeys. The middle cerebral artery was embolized by an autologous blood clot. Read More

View Article
December 2018

Nutrition, Energy Expenditure, Dysphagia, and Self-Efficacy in Stroke Rehabilitation: A Review of the Literature.

Brain Sci 2018 Dec 7;8(12). Epub 2018 Dec 7.

Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

While significant research has been performed regarding the use of thrombolytic agents and thrombectomy in the setting of acute stroke, other factors, such as nutritional status of stroke patients, is a less explored topic. The topic of nutrition is critical to the discussion of stroke, as up to half of stroke survivors may be considered malnourished at discharge. Dysphagia, old age, restricted upper limb movement, visuospatial impairment, and depression are all important risk factors for malnutrition in this cohort. Read More

View Article
December 2018

Pulmonary embolism caused by myasthenia gravis: A case report.

Medicine (Baltimore) 2018 Dec;97(49):e13578

Department of Respiratory Medicine, Qinghai University Affiliated Hospital, Xining, China.

Rationale: Pulmonary embolism (PE) is a relatively common disease; however, myasthenia gravis leading to PE has been rarely reported in the literature. We report a case of PE in a patient with myasthenia gravis and discuss the possible mechanism underlying the development of PE. We hypothesize that inflammatory mediators may lead to endothelial injury, resulting in PE or deep venous thrombosis (DVT) in patients with myasthenia gravis. Read More

View Article
December 2018

Statistical Analysis Plan for EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND) trial.

Int J Stroke 2018 Dec 7:1747493018816101. Epub 2018 Dec 7.

1 Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia.

Background: EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND) is a randomized, multicenter, double-blinded, placebo-controlled phase 3 trial to test the hypothesis of extending the thrombolysis time window to 9 h from stroke onset and in wake-up stroke (WUS) patients.

Objective: To formulate the detailed statistical analysis plan for the EXTEND trial prior to database lock. This statistical analysis plan is based on the published and registered EXTEND trial protocol and is developed by the blinded steering committee and management team. Read More

View Article
December 2018

Successful salvage of allograft dysfunction triggered by transplant renal vein thrombosis immediately after kidney transplantation: a case report.

Int J Nephrol Renovasc Dis 2018 23;11:321-327. Epub 2018 Nov 23.

Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan,

Background: Transplant renal vein thrombosis (TRVT) is a severe vascular complication and is caused by various factors, including recipient factors, donor factors, immunosuppression regimens, and surgical techniques. Despite adequate interventions, including thrombolytic therapy or surgical thrombectomy, successful salvage of the allograft is often difficult. We observed a case of TRVT induced by compression of the renal vein immediately after intraoperative abdominal closure. Read More

View Article
November 2018

Development of a novel RANKL-based peptide, microglial healing peptide1-AcN (MHP1-AcN), for treatment of ischemic stroke.

Sci Rep 2018 Dec 11;8(1):17770. Epub 2018 Dec 11.

Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka, Japan.

Although the regulation of post-ischemic inflammation is an important strategy to treat ischemic stroke, all clinical trials have failed to show its efficacy. To solve the problem, we previously developed a novel partial peptide of RANKL, microglial healing peptide 1 (MHP1), which could reduce ischemic injury by inhibiting Toll-like receptor (TLR) induced inflammation. However, optimization of the peptide was necessary to increase the stability and efficacies for clinical use. Read More

View Article
December 2018

Enhancing Base Excision Repair of Mitochondrial DNA to Reduce Ischemic Injury Following Reperfusion.

Transl Stroke Res 2018 Dec 8. Epub 2018 Dec 8.

Exscien Corp, Mobile, AL, 36688, USA.

We hypothesize that enhancing mitochondrial base excision repair (BER) capability in brain will reduce reperfusion-associated ischemic brain injury. Post-stroke reperfusion was modeled in mice via transient filament occlusion of the middle cerebral artery (60 min) (transient MCAO). Administration of a TAT-modified form of a DNA glycosylase (EndoIII) following reperfusion of the brain reduced resultant brain infarct volume. Read More

View Article
December 2018
1 Read

[Contemporary data on efficacy of anticoagulant therapy in recanalization of deep veins].

Angiol Sosud Khir 2018 ;24(4):185-190

Department for General Surgery and Urology, Volgograd State Medical University under the RF Ministry of Public Health, Volgograd, Russia.

The article is a literature review containing a detailed description of anticoagulant therapy variants, their efficacy in recanalization of deep veins, as well as patients' compliance to treatment. Russian specialists have demonstrated that the processes of active re-organization of thrombotic masses, in some cases leading to complete clearing of the vessel's lumen from a thrombus, may be observed at terms from 3 to 6 months, with a failure to occur within the above period reportedly followed by formation of irreversible cicatricial-sclerotic alterations in the veins. That is why adequate anticoagulant therapy should be initiated promptly in order to prevent the development of irreversible alterations and a decompensated form of chronic venous insufficiency. Read More

View Article
January 2018

Successful mechanical thrombectomy in stroke with thrombolysis-associated intracerebral hemorrhage-a case report.

J Stroke Cerebrovasc Dis 2018 Oct 24. Epub 2018 Oct 24.

Department of Neurology, University Hospital Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. Electronic address:

Background: Intravenous thrombolysis and mechanical thrombectomy are the standard of care for patients with acute ischemic stroke with large vessel occlusion. Intracerebral hemorrhage is a main complication of intravenous thrombolysis, however, no data are available on the efficacy and safety of mechanical thrombectomy in patients with thrombolysis-associated intracerebral hemorrhage. This constellation is expected to become more frequent as increasing numbers of patients are treated under the drip-and-ship paradigm. Read More

View Article
October 2018

Treatment-Related Outcomes in Paget-Schroetter Syndrome-A Cross-Sectional Investigation.

J Pediatr 2018 Dec 7. Epub 2018 Dec 7.

Division of Pediatric Hematology/Oncology, Nationwide Children's Hospital, Columbus, OH; Department of Pediatrics, The Ohio State University, Columbus, OH.

Objective: To investigate treatment-related outcomes, namely radiological clot resolution, post-thrombotic syndrome (PTS), and health related quality-of-life (HRQoL) scores, in children with Paget-Schroetter syndrome (PSS) undergoing multidisciplinary management, including anticoagulation and decompressive rib-resection surgery, with or without thrombolytic therapy.

Study Design: We identified all patients treated for PSS at our institution between the years 2010 and 2017. Baseline clinical and radiologic data were abstracted from medical records. Read More

View Article
December 2018
3.790 Impact Factor

Meta-Analysis of Prevalence and Short-Term Prognosis of Hemodynamically Unstable Patients With Symptomatic Acute Pulmonary Embolism.

Am J Cardiol 2018 Nov 26. Epub 2018 Nov 26.

Respiratory Department, Ramón y Cajal Hospital, Universidad de Alcalá (IRYCIS), Madrid, Spain. Electronic address:

There remains limited information about the prevalence and outcomes of hemodynamic unstable patients with acute pulmonary embolism (PE). We performed a systematic review and meta-analysis of prospective registries that enrolled patients with acute PE to assess the prevalence and prognostic significance of hemodynamic instability for the primary outcome of short-term all-cause mortality, and the secondary outcome of short-term PE-related mortality. We also assessed the association between use of thrombolytic therapy versus no use and short-term outcomes in the subgroup of unstable patients. Read More

View Article
November 2018
1 Read

Pulmonary embolectomy in a case of subacute pulmonary embolism, with previous unsuccessful fibrinolysis

Rev Med Inst Mex Seguro Soc 2018 11 30;56(4):418-423. Epub 2018 Nov 30.

Universidad Nacional Autónoma de México, Facultad de Medicina, División de Estudios de Posgrado. Ciudad de México, México

Background: Pulmonary embolism is a potentially fatal heart condition that requires prompt restoration of blood flow in the pulmonary vascular bed and prevention of recurrent events. Mortality is associated to the degree of hemodynamic repercussion, complications and opportunity in the treatment.

Case Report: Male 33 years of age who began with sudden dyspnea, chest pain of moderate intensity, sweating and syncope. Read More

View Article
November 2018
1 Read

Transient Q-waves in an infant with asymptomatic myocardial infarction due to Kawasaki disease.

Cardiol Young 2018 Dec 6:1-4. Epub 2018 Dec 6.

Department of Pediatrics,Shinshu University School of Medicine,Asahi 3-1-1, Matsumoto,Japan.

Giant coronary artery aneurysms are a complication of Kawasaki disease and can be fatal if associated with thrombosis. We describe the clinical outcome of a boy with Kawasaki disease who exhibited "supergiant" coronary artery aneurysms at the age of 14 months and, despite treatment with anticoagulant and antiplatelet medication, developed a left coronary artery thrombosis and presented following a myocardial infarction at 2 years old. Although his symptoms were minimal, the myocardial infarction was identified by abnormal Q-waves and giant negative T-waves in precordial leads of routine electrocardiography. Read More

View Article
December 2018
3 Reads

Thromboembolic Complications Following Tissue Plasminogen Activator Therapy in Patients of Acute Ischemic Stroke - Case Report and Possibility for Detection of Cardiac Thrombi.

Open Med (Wars) 2018 19;13:551-555. Epub 2018 Nov 19.

Division of Emergency and Critical Care Medicine, Department of Acute Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kamimachi, Itabashi-ku, Tokyo Japan.

Many reports focus on the probability of intracranial hemorrhage as a complication after recombinant tissue plasminogen activator (rt-PA) therapy. However, thromboembolic complications are not well discussed. We experienced a case in which severe thromboembolic complications occurred in the right radial and right ulnar artery. Read More

View Article
November 2018
1 Read

The Efficacy of IV Tissue Plasminogen Activator for Restoring Cerebral Blood Flow in the Hours Immediately after Administration in Patients with Acute Stroke.

J Neuroimaging 2018 Dec 3. Epub 2018 Dec 3.

National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.

Background And Purpose: Timely restoration of tissue-level cerebral blood flow is the goal of thrombolytic therapy in patients presenting with an acute ischemic stroke. We aimed to identify the incidence and predictors of reperfusion immediately following treatment with intravenous recombinant tissue plasminogen activator (IV rt-PA).

Methods: This study included patients with acute ischemic stroke triaged using magnetic resonance imaging (MRI) with perfusion-weighted imaging (PWI) and treated with IV rt-PA who were subsequently enrolled in our natural history study and underwent repeat MRI with PWI approximately 2 hours posttreatment. Read More

View Article
December 2018
1 Read

Fibrinogen concentrate replacement in ischemic stroke patients after recombinant tissue plasminogen activator treatment.

Adv Clin Exp Med 2018 Dec 3. Epub 2018 Dec 3.

Stroke Unit, Neurology Clinic, Department of Neuroscience, Nuovo Ospedale Civile S. Agostino-Estense, University of Modena and Reggio Emilia, Modena, Italy.

Background: Post-thrombotic intracerebral hemorrhage (ICH) is experienced by 6-8% of stroke patients and is associated with multiple factors, including acquired coagulopathy induced by the thrombolytic drug.

Objectives: The objective of this study was to assess the outcome of the intravenous (IV) administration of fibrinogen concentrate in a series of acute stroke patients who developed iatrogenic fibrinogen critical depletion after IV thrombolysis.

Material And Methods: Of the 39 ischemic stroke patients treated with IV thrombolysis with a severe hypofibrinogenemia requiring infusion with IV fibrinogen concentrate, 30 patients were treated with 2 g of IV recombinant tissue plasminogen activator (rt-PA), followed by further doses until the fibrinogen level reached 200 mg/dL in hemorrhagic patients or 100 mg/dL in non-hemorrhagic patients, and 9 were treated with IV rt-PA followed by endovascular thrombectomy. Read More

View Article
December 2018
1 Read

Preclinical Validation of the Therapeutic Potential of Glasgow Oxygen Level Dependent (GOLD) Technology: a Theranostic for Acute Stroke.

Transl Stroke Res 2018 Nov 30. Epub 2018 Nov 30.

Institute of Neuroscience & Psychology, College of Medicine, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland, UK.

In acute stroke patients, penumbral tissue is non-functioning but potentially salvageable within a time window of variable duration and represents target tissue for rescue. Reperfusion by thrombolysis and/or thrombectomy can rescue penumbra and improve stroke outcomes, but these treatments are currently available to a minority of patients. In addition to the utility of Glasgow Oxygen Level Dependent (GOLD) as an MRI contrast capable of detecting penumbra, its constituent perfluorocarbon (PFC) oxygen carrier, combined with normobaric hyperoxia, also represents a potential acute stroke treatment through improved oxygen delivery to penumbra. Read More

View Article
November 2018

Acute anterior myocardial infarction in the 36th week of pregnancy: A successful stepwise treatment approach.

Turk Kardiyol Dern Ars 2018 12;46(8):702-705

Department of Cardiology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey.

Acute myocardial infarction (AMI) is associated with a high incidence of maternal and fetal complications when it develops during pregnancy or the early postpartum period. The pathophysiology involves various factors, including alterations in the vascular wall and hypercoagulability as a result of the hormonal and hemodynamic effects of pregnancy. It frequently occurs due to the development of a thrombus following a ruptured plaque. Read More

View Article
December 2018
1 Read

Thrombosis in the portal venous system caused by hypereosinophilic syndrome: A case report.

Medicine (Baltimore) 2018 Nov;97(48):e13425

Department of Critical Care Medicine, Nantong Third People's Hospital, Nantong University.

Rationale: Extensive thrombosis in the portal venous system caused by hypereosinophilic syndrome (HES) is rare, and there is no consensus on anticoagulant and thrombolytic treatments for arteriovenous thrombosis caused by HES.

Patient Concerns: The clinical data of a patient with extensive thrombosis in his portal venous system (superior mesenteric, splenic, hepatic, and portal veins), renal artery thrombosis, and mesenteric thrombosis caused by HES with secondary gastrointestinal bleeding and intestinal necrosis were retrospectively analyzed. Before admission, his eosinophil count increased to 7. Read More

View Article
November 2018
3 Reads

Reply to the letter "Thrombolytic therapy to the patients with de Winter electrocardiographic pattern, not right".

QJM 2018 Nov 28. Epub 2018 Nov 28.

From the Department of Cardiology, Second Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.

View Article
November 2018

Thrombolytic therapy to the patients with de Winter electrocardiographic pattern, not riht.

QJM 2018 Nov 28. Epub 2018 Nov 28.

Department of Cardiology, Shenzhen Baoan District Hospital of traditional Chinese Medicine,PR China.

View Article
November 2018
3 Reads

Treatment With Intravenous Alteplase for Acute Ischemic Stroke After Reversal of Dabigatran With Idarucizumab: A Case Study.

J Neurosci Nurs 2018 Nov 27. Epub 2018 Nov 27.

Elizabeth O'Brien, GradDipNeuroSci, MNNP, is Stroke Nurse Practitioner, Neurology Department, Royal North Shore Hospital, St Leonards, Australia.

Treatment options for anticoagulated patients presenting with ischemic stroke are limited. Off-label use of idarucizumab to rapidly reverse the anticoagulant effect of dabigatran may ensure eligibility for thrombolytic therapy with alteplase. This case describes a 77-year-old white male who presented to the hospital 89 minutes after sudden onset of right-sided hemiparesis, dysarthria, and facial palsy. Read More

View Article
November 2018
4 Reads

Pharmaco-invasive Therapy with Fibrinolytic Agents: A Potent Lifesaving Reperfusion Strategy in STEMI Patients in Metro Tier-I Cities in India.

J Assoc Physicians India 2018 May;66(5):76-81

Abbott Health Care Pvt. Ltd., Mumbai, Maharashtra.

Background: Primary Sjogren's Syndrome (pSS) with Hypokalemic Periodic Paralysis(HPP) whether an association or a different clinical subset needs review.

Aim: To generate a consensus on the importance of pharmaco-invasive therapy for STEMI patients when primary PCI cannot be expeditiously performed in metro and tier-I cities in India.

Methodology: A total of 8 expert panel groups comprising 48 experts from Cardiology specialty in India were convened. Read More

View Article
May 2018
4 Reads

In vitro evaluation of Cuscuta reflexa Roxb. for thrombolytic, antioxidant, membrane stabilizing and antimicrobial activities.

Nat Prod Res 2018 Nov 26:1-4. Epub 2018 Nov 26.

a Faculty of Pharmacy , International Islamic University Malaysia , Kuantan , Pahang , Malaysia.

The key purpose of this experiment was to evaluate the thrombolytic, antioxidant, membrane stabilizing and antimicrobial potentials of crude ethanol extracts (CEE) of whole plant, organic and aqueous soluble fractions (OF & AQSF). CEE showed the highest (44.63%) clot lysis activity compared to streptokinase (64. Read More

View Article
November 2018
4 Reads
0.920 Impact Factor

Quantitative Characterization of the Hemorrhagic, Necrotic, Coagulation-Altering Properties and Edema-Forming Effects of Zebra Snake () Venom.

J Toxicol 2018 24;2018:6940798. Epub 2018 Oct 24.

Department of Wildlife Management and Ecotourism, Katima Mulilo Campus, Faculty of Agriculture and Natural Resources, University of Namibia, P. Bag 1096, Ngweze, Katima Mulilo, Namibia.

This study was designed to investigate the cytotoxicity and haemotoxicity of the Western barred (zebra) spitting cobra () venom to help explain atypical and inconsistent reports on syndromes by Namibian physicians treating victims of human ophidian accidents. Freeze-dried venom milked from adult zebra snakes was dissolved in phosphate buffered saline (PBS) for use in this study. Haemorrhagic and necrotic activity of venom were studied in New Zealand albino rabbits. Read More

View Article
October 2018
3 Reads

Synthesis in Escherichia coli and Characterization of Human Recombinant Erythropoietin with Additional Heparin-Binding Domain.

Biochemistry (Mosc) 2018 Oct;83(10):1207-1221

Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, 123098, Russia.

Recombinant human erythropoietin (EPO) with additional N-terminal heparin-binding protein domain (HBD) from bone morphogenetic protein 2 was synthesized in Escherichia coli cells. A procedure for HBD-EPO purification and refolding was developed for obtaining highly-purified HBD-EPO. The structure of recombinant HBD-EPO was close to that of the native EPO protein. Read More

View Article
October 2018
1 Read

Potential molecular targets of peroxynitrite in mediating blood-brain barrier damage and haemorrhagic transformation in acute ischaemic stroke with delayed tissue plasminogen activator treatment.

Free Radic Res 2018 Nov 23:1-20. Epub 2018 Nov 23.

a School of Chinese Medicine , the University of Hong Kong , PR China.

Tissue plasminogen activator (t-PA) remains to be the only FDA-approved drug for ischaemic stroke, but it has a restrictive therapeutic window with 4.5 hours. Beyond the golden time window, thrombolytic treatment carries the risk of haemorrhagic transformation (HT). Read More

View Article
November 2018
6 Reads

The role of calcium handling mechanisms in reperfusion injury.

Curr Pharm Des 2018 11 20. Epub 2018 Nov 20.

2nd Department of Cardiology, MedicalSchool, AttikonHospital, National and KapodistrianUniversity of Athens. Greece.

Cardiovascular diseases, such as stroke and myocardial infarction (MI) remain the major cause of death and disability worldwide. However, the mortality of MI has declined dramatically over the past several decades because of advances in medicines (thrombolytic agents, antiplatelet drugs, beta blockers, and angiotensin converting enzyme inhibitors) and approaches to restore tissue perfusion(percutaneous coronary intervention and cardiopulmonary bypass). Animals studies have been shown that these treatments have been effective in reducing acute myocardial ischemic injury and limiting MI size. Read More

View Article
November 2018
6 Reads

Efficacy evaluation of reteplase in a novel canine acute pulmonary thromboembolism model developed by minimally invasive surgery and digital subtraction angiography.

Drug Des Devel Ther 2018 1;12:3717-3730. Epub 2018 Nov 1.

Laboratory of Nonhuman Primate Disease Modeling Research, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China,

Purpose: In order to evaluate the thrombolytic effects of reteplase in pulmonary thromboembolism (PTE), we developed a novel canine PTE model. The efficacy of reteplase against PTE in comparison to alteplase was clarified for the first time, and this PTE model could be further applied to studies of novel thrombolytic therapies.

Patients And Methods: Twenty-four dogs were divided into four groups: sham operation, vehicle, alteplase, and reteplase. Read More

View Article
November 2018
5 Reads

Low Cholesterol Levels Increase Symptomatic Intracranial Hemorrhage Rates After Intravenous Thrombolysis: A Multicenter Cohort Validation Study.

J Atheroscler Thromb 2018 Nov 21. Epub 2018 Nov 21.

School of Public Health, College of Public Health, Taipei Medical University.

Aim: Although a lower level of non-high-density lipoprotein cholesterol (HDL-C) was reported to be inversely associated with spontaneous intracranial hemorrhage (ICH), no enough evidence has verified whether lipid profiles modify hemorrhagic transformation and functional outcomes in patients with acute ischemic treated with thrombolysis.

Methods: This multicenter cohort study included 2373 patients with acute ischemic stroke treated with intravenous thrombolysis between December 2004 and December 2016. Of these, 1845 patients were categorized into either the hyperlipidemia or non-hyperlipidemia group. Read More

View Article
November 2018
2 Reads

Use of argatroban for extracorporeal life support in patients with nonheparin-induced thrombocytopenia: Analysis of 10 consecutive patients.

Medicine (Baltimore) 2018 Nov;97(47):e13235

Department of Thoracic and Cardiovascular Surgery.

Unfractionated heparin (UFH) is currently the standard anticoagulant used in extracorporeal life support (ECLS). However, severe thrombocytopenia occurs frequently during ECLS use and it may be difficult to determine whether this represents heparin-induced thrombocytopenia (HIT) or not. In this case, UFH cannot be continued. Read More

View Article
November 2018
1 Read

The combination of Caprini risk assessment scale and thrombotic biomarkers to evaluate the risk of venous thromboembolism in critically ill patients.

Medicine (Baltimore) 2018 Nov;97(47):e13232

Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.

To evaluate the correlation between the Caprini risk assessment scale and plasma thrombosis biomarkers and estimate the validity of this method in identifying critically ill patients at high risk of venous thromboembolism (VTE).Patients with VTE who were admitted to the intensive care unit (ICU) department of West China Hospital SiChuan University from October 2016 to October 2017 were enrolled in this case-control study. We retrieved relative clinical data and laboratory test results included in the Caprini risk assessment scale to calculate the Caprini score and compared thrombosis biomarkers between various risk stratifications (low, moderate, high, and highest). Read More

View Article
November 2018
4 Reads

Lymphocyte hydrogen sulfide production predicts intravenous immunoglobulin resistance in children with Kawasaki disease: A preliminary, single-center, case-control study.

Medicine (Baltimore) 2018 Nov;97(47):e13069

School of Public Health, Xi'an Jiaotong University, Xian.

The aim of the study was to identify whether lymphocyte hydrogen sulfide production is a potential biomarker to predict intravenous immunoglobulin (IVIG) resistance in children with Kawasaki disease (KD).This preliminary, single-center, case-control study conducted between June 2016 and March 2018 in Shaanxi Provincial People's Hospital, 85 children (50 with KD and 35 healthy controls) were included. Laboratory biomarkers were collected from the medical records. Read More

View Article
November 2018
2 Reads

Salvianolate injection in the treatment of acute cerebral infarction: A systematic review and a meta-analysis.

Medicine (Baltimore) 2018 Nov;97(47):e12374

Department of Neurology, TianJin First Hospital.

To evaluate the effectiveness and safety of Salvianolate injection (SI) in the treatment of acute cerebral infarction (ACI).We electronically searched databases including PubMed, The Cochrane Library, EMBASE, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure, and WanFang Data to collect randomized controlled trials (RCTs) focused on SI treating ACI up to August 2017. Two reviewers independently screened literatures, extracted data, and assessed the risk of bias of included studies. Read More

View Article
November 2018
6 Reads

New concepts on acute ocular ischemia.

Curr Opin Neurol 2018 Nov 15. Epub 2018 Nov 15.

Department of Ophthalmology.

Purpose Of Review: To review recent advances in the management of acute ocular ischemic events, including: transient monocular vision loss, central and branch retinal artery occlusions, and nonarteritic anterior ischemic optic neuropathy.

Recent Findings: Transient monocular vision loss and acute retinal arterial occlusions require immediate diagnosis and management, with recognition of these events as transient ischemic attack or stroke equivalents, respectively. Patients should undergo an immediate stroke workup in a stroke center, similar to patients with acute cerebral ischemia. Read More

View Article
November 2018
2 Reads

Thrombolysis Enhancing by Magnetic Manipulation of Fe₃O₄ Nanoparticles.

Materials (Basel) 2018 Nov 17;11(11). Epub 2018 Nov 17.

School of Economics and Management, Shanghai University of Electric Power, Shanghai 200090, China.

In this paper, an effective method of accelerating urokinase-administrated thrombolysis through a rotating magnetic field (RMF) of guided magnetic nanoparticles (NPs) in the presence of low-dose urokinase is proposed. The dispersed Fe₃O₄ NPs mixed with urokinase were injected into microfluidic channels occluded by thrombus prepared in vitro. These magnetic NPs aggregated into elongated clusters under a static magnetic field, and were then driven by the RMF. Read More

View Article
November 2018
2.651 Impact Factor

Organizing stroke systems in the field for patients with suspected large vessel occlusion acute stroke.

Expert Rev Cardiovasc Ther 2018 Nov 19:1-7. Epub 2018 Nov 19.

a Department of Clinical Neurosciences , Cumming School of Medicine, University of Calgary , Calgary , Canada.

Introduction: The dawn of endovascular stroke therapy has reshaped stroke care. Eligible patients need to be rushed to capable centers for intervention. This may entail bypassing closer hospitals that could confirm the diagnosis, administer thrombolytic therapy, then transfer patients for intervention. Read More

View Article
November 2018
1 Read

Central retinal artery occlusion.

Indian J Ophthalmol 2018 Dec;66(12):1684-1694

Department of Ophthalmology and Visual Sciences, College of Medicine, University of Iowa, Iowa City, Iowa, USA.

The pathogeneses, clinical features, and management of central retinal artery occlusion (CRAO) are discussed. CRAO consists of the following four distinct clinical entities: non-arteritic CRAO (NA-CRAO), transient NA-CRAO, NA-CRAO with cilioretinal artery sparing, and arteritic CRAO. Clinical characteristics, visual outcome, and management very much depend upon the type of CRAO. Read More

View Article
December 2018

Sensitivity of treatment recommendations to bias in network meta-analysis.

J R Stat Soc Ser A Stat Soc 2018 Jun 6;181(3):843-867. Epub 2017 Dec 6.

University of Bristol UK.

Network meta-analysis (NMA) pools evidence on multiple treatments to estimate relative treatment effects. Included studies are typically assessed for risk of bias; however, this provides no indication of the impact of potential bias on a decision based on the NMA. We propose methods to derive bias adjustment thresholds which measure the smallest changes to the data that result in a change of treatment decision. Read More

View Article
June 2018
2 Reads

The utility of intravenous heparin to aid diagnosis and intervention in obscure GI bleeding.

Gastrointest Endosc 2018 12;88(6):974

Academic Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals, Sheffield, UK.

View Article
December 2018
3 Reads

Comorbid cancer and use of thrombolysis in acute pulmonary embolism.

J Thromb Thrombolysis 2018 Nov 17. Epub 2018 Nov 17.

College of Pharmacy, Medical University of South Carolina, 280 Calhoun Street, QE213C MSC140, Charleston, SC, 29425, USA.

Guidelines suggest the use of thrombolytic therapy for acute pulmonary embolism (PE) patients with hypotension who are not at high-risk of bleeding. Data describing the use of thrombolysis in patients with cancer are scarce. The aim of this study was to evaluate the relationship between cancer and the use of thrombolysis for acute PE. Read More

View Article
November 2018
3 Reads

New progress in the approaches for blood-brain barrier protection in acute ischemic stroke.

Brain Res Bull 2018 Nov 15;144:46-57. Epub 2018 Nov 15.

Department of Neurology, The Second Xiangya Hospital,Central South University, Changsha, Hunan 410011, China. Electronic address:

Ischemic stroke is a disease with high morbidity and mortality worldwide, which often places an additional strain on families and society due to the poor prognosis. Blood brain-barrier (BBB) damage is the critical pathological process, which contributes to hemorrhagic transformation (HT) and poor prognosis in cerebral ischemia. Thus, there is a pressing need to seek an approach to ameliorate BBB damage and reduce the HT that can be induced by fibrinolytic therapy involving recombinant tissue plasminogen activator (rtPA) in clinical practice. Read More

View Article
November 2018
7 Reads

A high titer of acquired factor V inhibitor in a hemodialysis patient who developed arterial thrombosis.

Int J Hematol 2018 Nov 16. Epub 2018 Nov 16.

Japanese Collaborative Research Group on Autoimmune Coagulation Factor Deficiencies (JCRG supported by the Japanese Ministry of Health, Labor and Welfare), Yamagata, Japan.

An 87-year-old man with diabetes mellitus was admitted to control recurrent bleeding from hemodialysis puncture sites. He was a smoker and had been diagnosed with arteriosclerosis obliterans. His PT and APTT were markedly prolonged, and all coagulation factors were markedly decreased (factor V [FV] activity < 1%) or below the measurement threshold, with the exception of fibrinogen and factor XIII. Read More

View Article
November 2018
6 Reads

Recent advances in the development of neuroprotective agents and therapeutic targets in the treatment of cerebral ischemia.

Eur J Med Chem 2018 Nov 7;162:132-146. Epub 2018 Nov 7.

Department of Neurosurgery, Changhai Hospital, Second Military Medical University, Shanghai, 200433, People's Republic of China. Electronic address:

Stroke is a central nervous system disease that seriously affects people's quality of life and has the second highest rate of morbidity and mortality in the world. At present, clinical treatment strategies for acute ischemic stroke are mainly thrombolytic and thrombectomy therapy. However, these strategies are not able to protect patients from ischemic injuries. Read More

View Article
November 2018
6 Reads

Outpatient treatment of proximal deep vein thrombosis.

Authors:
Dalibor Musil

Vnitr Lek 2018 ;64(9):887-892

The treatment of deep vein thrombosis (DVT) is based on anticoagulation with heparin, warfarin and direct oral anti-coagulants. According to the 9th ACCP Recommendation, for patients with DVT of the lower limbs, where the clinical state and home conditions permit, preference is given to home treatment over hospitalization. Despite that, the majority of patients with acute DVT still tend to be hospitalized, in particular when proximal thrombosis from the popliteal vein upward is involved. Read More

View Article
January 2018
1 Read

Intraoperative catheter directed thrombolytic therapy for the treatment of superior mesenteric and portal Vein thrombosis.

Int J Surg Case Rep 2018 Oct 5;53:242-245. Epub 2018 Oct 5.

BDF Hospital, Bahrain. Electronic address:

Introduction And Case Presentation: Acute portal and superior mesenteric vein thrombosis(SMV) is a rare but potentially lethal condition that is often characterized by generalized and non-specific symptoms. A high index of suspicion is warranted for early diagnosis and management. We present a case of 54 year old male who presented with generalized abdominal pain which was later accompanied by hemodynamic instability and radiological diagnosis of portal vein and superior mesenteric vein thrombosis. Read More

View Article
October 2018
4 Reads